IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.332
AS - Asia 13.753
EU - Europa 10.027
SA - Sud America 1.799
AF - Africa 363
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 34
Totale 42.346
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.961
CN - Cina 6.933
SG - Singapore 2.838
IE - Irlanda 2.213
HK - Hong Kong 1.684
UA - Ucraina 1.569
BR - Brasile 1.341
FI - Finlandia 1.177
DE - Germania 1.134
VN - Vietnam 1.090
RU - Federazione Russa 898
SE - Svezia 752
IT - Italia 692
FR - Francia 678
GB - Regno Unito 494
IN - India 265
CA - Canada 183
AR - Argentina 167
BD - Bangladesh 136
ZA - Sudafrica 133
MX - Messico 116
IQ - Iraq 98
PK - Pakistan 87
TR - Turchia 77
JP - Giappone 76
NL - Olanda 73
CO - Colombia 65
PL - Polonia 60
ID - Indonesia 58
SA - Arabia Saudita 53
EC - Ecuador 52
VE - Venezuela 51
UZ - Uzbekistan 48
ES - Italia 47
AT - Austria 46
MA - Marocco 40
CL - Cile 37
BE - Belgio 36
AU - Australia 32
KE - Kenya 32
PH - Filippine 30
IR - Iran 29
MY - Malesia 27
TN - Tunisia 25
EG - Egitto 24
JO - Giordania 24
PY - Paraguay 24
CZ - Repubblica Ceca 23
BO - Bolivia 21
LT - Lituania 21
AE - Emirati Arabi Uniti 20
EU - Europa 20
IL - Israele 20
MU - Mauritius 20
PA - Panama 19
NP - Nepal 18
ET - Etiopia 17
PE - Perù 17
UY - Uruguay 17
AZ - Azerbaigian 16
DZ - Algeria 16
KR - Corea 15
DK - Danimarca 13
LB - Libano 13
RO - Romania 13
KZ - Kazakistan 11
PT - Portogallo 11
SN - Senegal 11
CR - Costa Rica 10
OM - Oman 10
BG - Bulgaria 9
JM - Giamaica 9
PS - Palestinian Territory 9
RS - Serbia 9
CH - Svizzera 8
DO - Repubblica Dominicana 8
LV - Lettonia 8
NG - Nigeria 8
XK - ???statistics.table.value.countryCode.XK??? 8
AL - Albania 7
KG - Kirghizistan 7
KW - Kuwait 7
MD - Moldavia 7
SK - Slovacchia (Repubblica Slovacca) 7
BH - Bahrain 6
NI - Nicaragua 6
SY - Repubblica araba siriana 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AM - Armenia 5
GE - Georgia 5
GR - Grecia 5
TH - Thailandia 5
BW - Botswana 4
BY - Bielorussia 4
HN - Honduras 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
ML - Mali 4
NZ - Nuova Zelanda 4
QA - Qatar 4
Totale 42.263
Salva come PNG Salva come JPEG
Città #
Chandler 2.219
Dublin 2.209
Jacksonville 1.999
Hong Kong 1.639
Nanjing 1.557
Singapore 1.410
San Jose 1.349
Ashburn 1.296
Dallas 1.199
Beijing 850
Boardman 781
Nanchang 615
Princeton 515
Lauterbourg 506
Lawrence 494
Wilmington 489
Hebei 462
Shenyang 456
Changsha 412
Ho Chi Minh City 397
Los Angeles 384
Jiaxing 372
Medford 349
Helsinki 257
Hangzhou 249
Hanoi 239
Tianjin 238
New York 228
Ann Arbor 206
Buffalo 200
Milan 154
Redondo Beach 150
Moscow 133
Munich 133
Shanghai 126
Woodbridge 111
São Paulo 104
Norwalk 96
Toronto 91
Orem 83
Johannesburg 82
Santa Clara 81
Seattle 77
Verona 77
Pavia 72
The Dalles 70
Nuremberg 67
Tokyo 66
Turku 62
Jinan 61
Frankfurt am Main 59
Da Nang 58
Chicago 56
Haiphong 56
Falls Church 54
Brooklyn 53
Guangzhou 53
Chennai 52
Warsaw 51
Zhengzhou 49
Falkenstein 48
San Francisco 47
Washington 45
Fairfield 42
Mexico City 42
Montreal 42
Tashkent 42
Baghdad 40
Houston 40
Kunming 40
Stockholm 39
Des Moines 38
Rome 38
Ningbo 37
London 36
Rio de Janeiro 36
Atlanta 35
Belo Horizonte 34
Brussels 34
Council Bluffs 33
Taizhou 31
Hải Dương 29
Boston 28
Denver 28
Nairobi 28
Manchester 27
Curitiba 26
Phoenix 25
Columbus 24
Amsterdam 22
Lahore 22
Amman 21
Biên Hòa 21
Brasília 21
Poplar 21
Tappahannock 21
Vienna 21
Buenos Aires 20
Dhaka 19
Guarulhos 19
Totale 27.275
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 185
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 178
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 170
A B-cell lymphoproliferative disorder 170
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 166
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data 163
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 154
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 154
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 152
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 149
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 148
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 148
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 143
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 143
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 142
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 141
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 141
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 140
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 139
Blast phase of essential thrombocythemia: A single center study. 137
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 137
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 136
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 136
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 135
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 135
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 135
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 134
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 134
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 133
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 133
A case of persistent eosinophilia 132
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 130
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 129
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 127
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 127
Classification and prognostic evaluation of myelodysplastic syndromes 126
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 125
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 124
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 124
Anemia associata ad endocrinopatie. 123
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 122
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 121
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. 120
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 120
A gain-of-function mutation of JAK2 in myeloproliferative disorders 120
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 119
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 119
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation 119
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 117
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 117
A chronic lymphoproliferative disorder 117
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 116
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 116
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 115
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 115
Clinical significance of somatic mutation in unexplained blood cytopenia 115
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 114
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 114
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 113
Cerebrospinal fluid ferritin in human disease. 113
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 113
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 112
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 110
Clinical and biological implications of driver mutations in myelodysplastic syndromes 110
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 110
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 109
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 108
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. 108
JAK2 (V617F) mutation in healthy individuals 108
Ittero. 107
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 107
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 107
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 107
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 106
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 106
Hematologic passport for athletes competing in endurance sports: a feasibility study. 106
Allelic imbalance in CALR somatic mutagenesis 106
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 106
A patient-oriented approach to treatment of myelodysplastic syndromes. 106
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 105
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 105
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells 105
Relationship between clone metrics and clinical outcome in clonal cytopenia 104
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 104
Pincered red cells and hereditary spherocytosis. 104
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 104
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 104
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 104
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 104
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 104
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 104
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 104
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. 104
Revised international prognostic scoring system for myelodysplastic syndromes 104
Further concerns about the medical risks of blood doping. 103
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 103
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. 103
Classification of anaemia on the basis of ferrokinetic parameters. 103
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 103
A global strategy for prevention and detection of blood doping with erythropoietin and related drugs 103
Totale 12.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.533
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.533
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021897 0 0 0 0 0 0 0 0 0 439 374 84
2021/20222.188 32 8 65 39 101 130 40 119 120 93 340 1.101
2022/20236.356 743 374 47 520 634 706 3 403 2.629 33 164 100
2023/20242.266 253 446 95 204 219 618 65 137 15 53 60 101
2024/20255.893 156 567 173 188 109 216 239 540 1.230 224 677 1.574
2025/202613.787 1.044 1.234 1.656 1.792 1.504 761 3.040 594 1.224 938 0 0
Totale 42.911